Zacks: Analysts Set $255.00 Target Price for Mesa Laboratories, Inc. (MLAB)

Mesa Laboratories, Inc. (NASDAQ:MLAB) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price target of $255.00 for the company and are predicting that the company will post $2.13 EPS for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 96 out of 255 based on the ratings given to related companies.

Several research firms have issued reports on MLAB. BidaskClub downgraded Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 9th. Zacks Investment Research downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 9th. Sidoti initiated coverage on Mesa Laboratories in a report on Wednesday. They set a “neutral” rating on the stock. Finally, TheStreet upgraded Mesa Laboratories from a “c” rating to a “b-” rating in a report on Friday, February 8th.

NASDAQ MLAB opened at $235.90 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.20 and a current ratio of 1.57. The stock has a market cap of $912.46 million, a price-to-earnings ratio of 38.17 and a beta of 0.38. Mesa Laboratories has a 1 year low of $131.51 and a 1 year high of $241.83.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Monday, February 4th. The medical instruments supplier reported $1.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.01. The firm had revenue of $26.68 million for the quarter, compared to the consensus estimate of $25.80 million. Mesa Laboratories had a return on equity of 23.53% and a net margin of 9.98%. On average, sell-side analysts expect that Mesa Laboratories will post 5.1 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Thursday, February 28th were issued a $0.16 dividend. The ex-dividend date was Wednesday, February 27th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.27%. Mesa Laboratories’s dividend payout ratio is 10.36%.

In other Mesa Laboratories news, Director Seg Ventures, Llc bought 20,000 shares of the company’s stock in a transaction dated Sunday, December 30th. The shares were bought at an average price of $23.10 per share, for a total transaction of $462,000.00. Following the acquisition, the director now directly owns 120,000 shares of the company’s stock, valued at $2,772,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert V. Dwyer sold 5,575 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $232.00, for a total value of $1,293,400.00. Following the completion of the transaction, the director now owns 53,913 shares in the company, valued at approximately $12,507,816. The disclosure for this sale can be found here. Insiders sold a total of 19,158 shares of company stock worth $4,450,329 in the last quarter. 15.00% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of MLAB. Bronfman E.L. Rothschild L.P. bought a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $34,000. Huntington National Bank bought a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $52,000. Quantamental Technologies LLC bought a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $83,000. Bessemer Group Inc. bought a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $125,000. Finally, Legal & General Group Plc grew its stake in shares of Mesa Laboratories by 14.1% in the 4th quarter. Legal & General Group Plc now owns 656 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 81 shares in the last quarter. Institutional investors own 76.33% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Featured Article: What is a Lock-Up Period?

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.